Jeffrey Larson

ORCID: 0000-0001-9924-2082

Also affiliated with JPMorgan Chase & Co (United States), Quantum Technology Sciences (United States), National Institutes for Quantum Science and Technology, University of Oklahoma

Computer ScienceMathematicsEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.”.

Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3018

N/A

0DataRank · unranked

15 citations

David Vining, Sukeshi Patel Arora, Sofia de Achaval, Jeffrey Larson, Carrie Cartwright +4 more